Buoyed by early discoveries, P&G expanded its pharmaceutical operations with the acquisition of Norwich Eaton Pharmaceuticals in 1982. Norwich gave P&G an innovative pharmaceutical Research & Development group that discovered and developed more prescription products including Entex, Macrodantin and Dantrium.
 Through the 1980s, P&G hired more researchers, modernized and expanded its R&D facilities and focused its research efforts. Additionally, P&G embarked on an effort to strengthen its marketing presence in international markets. In the late 80's P&G made strategic international acquisitions in France with Nativelle, in Germany with Rohm Pharma, and in Italy with the acquisition of some Smith, Kline French brands.
In 1992, on the 10th anniversary of its acquisition, the separate organizations of Norwich Eaton Pharmaceuticals and the P&G Specialty Products group were officially combined and renamed Procter & Gamble Pharmaceuticals. Three years later P&G opened a new site. This 1.3 million square foot facility based in Cincinnati, now serves as P&G’s global health care head quarters for pharmaceuticals, over-the-counter, and oral care businesses.
By 2000, our sales had grown five-fold from the early '80's and new pharmacological treatments were added to the lineup. These included Asacol, Macrobid and Actonel.
We recently made the strategic decision to no longer conduct internal upstream pharmaceutical research to invent new therapies. Instead, we partner with leaders in the biotech and pharmaceutical industry to form mutually beneficial partnerships and develop/market new treatments. We’ve also changed our core focus areas to deliver better therapeutic solutions faster.
 Today, we market about 40 prescription drugs worldwide and have annual global sales of more than $2 billion. We continue to build our current portfolio of prescription brands and strengthen our pipeline by forging collaborative relationship with leaders in research innovation who focus on our therapeutic areas of interest.
|
